Expanded Clinical Use of Nasalferon in COVID-19

Not Applicable

Not yet recruiting

• Conditions: COVID-19; SARS-CoV-2; Coronavirus Infections; SARS Virus; Coronaviridae Infections; Nidovirales Infections; Betacoronavirus

• Registration Number: RPCEC00000396
• Lead Sponsor: Center for Genetic Engineering and Biotechnology (CIGB)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-10
• Study Completion: 2022-01-31
• Results First Posted: 2022-03-31
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Low risk suspect, mild symptomatic, with positive antigen test.
2. Confirmed low risk, asymptomatic and mild symptomatic, with positive PCR.
3. Voluntariness of the patient or legal representative.

Exclusion Criteria

1. Individuals confirmed COVID-19 and classified as medium and high risk.
2. Individuals with hypersensitivity to thiomersal (thimerosal).
3. Individuals with hypersensitivity to interferon alpha

Study & Design

• Study Type: Interventional
• Study Design: Not specified